Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):429–437. doi: 10.1038/bjc.1992.88

Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.

A M Oza 1, T S Ganesan 1, M Dorreen 1, P W Johnson 1, J Waxman 1, W Gregory 1, J Lim 1, J Wright 1, L Dadiotis 1, V Barbounis 1, et al.
PMCID: PMC1977592  PMID: 1558800

Abstract

A total of 164 consecutive adults with newly confirmed stage IIIB, IVA or IVB Hodgkin's disease (HD) commenced cyclical combination chemotherapy comprising mustine, vinblastine, prednisolone and procarbazine (MVPP) every 6 weeks (145 patients) or minor variants (19) at St Bartholomew's Hospital between 1968 and 1984. The median follow-up period is 14 years. Complete remission (CR) was achieved in 97/164 (59%) and partial remission (PR) in 23/164 (14%) with lesser responses or death being documented in 44. Achievement of CR correlated with stage, serum albumin and serum beta2 microglobulin level at presentation on univariate and multivariate analysis; 55/97 (58%) remain in continuous CR, the median duration of remission not having been reached. Twelve patients died in first remission; there have been 30 recurrences, one occurring after 13 years. Second remission was achieved in 17/30; 6/17 remain in continuous second remission and two have died in second remission. There have been nine second recurrences, third remission being achieved in 6/9. Two continue in third remission, two patients have died in third remission: 82/164 patients are alive with a minimum follow-up of 6 years. Eighty-two patients have died; 66 with evidence of HD, six with second malignancy, one each of haemorrhage and infection, eight of unrelated causes, the cause of death was unknown in one. The overall median survival from presentation is 14 years, being the same for patients in CR and PR with minimal residual abnormality (good partial remission, GPR), and being better for those for whom remission was achieved than those for whom it was not. The median survival following first recurrence is 4 years, being significantly longer for younger patients (less than 50 years). These results emphasise the importance of long-term follow-up to determine the clinical course of HD and are vital for planning experimental chemotherapy at the time of early treatment failure or recurrence.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amlot P. L., Adinolfi M. Serum beta 2 microglobulin and its prognostic value in lymphomas. Eur J Cancer. 1979 May;15(5):791–796. doi: 10.1016/0014-2964(79)90155-5. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739–746. doi: 10.7326/0003-4819-104-6-739. [DOI] [PubMed] [Google Scholar]
  3. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  4. Carella A. M., Congiu A. M., Gaozza E., Mazza P., Ricci P., Visani G., Meloni G., Cimino G., Mangoni L., Coser P. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol. 1988 Sep;6(9):1411–1416. doi: 10.1200/JCO.1988.6.9.1411. [DOI] [PubMed] [Google Scholar]
  5. Chapman R. M., Sutcliffe S. B., Malpas J. S. Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effects on sexual function. JAMA. 1979 Oct 26;242(17):1882–1884. [PubMed] [Google Scholar]
  6. Chapman R. M., Sutcliffe S. B., Malpas J. S. Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA. 1981 Apr 3;245(13):1323–1328. [PubMed] [Google Scholar]
  7. Child J. A., Spati B., Illingworth S., Barnard D., Corbett S., Simmons A. V., Stone J., Worthy T. S., Cooper E. H. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. Cancer. 1980 Jan 15;45(2):318–326. doi: 10.1002/1097-0142(19800115)45:2<318::aid-cncr2820450220>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  8. Coleman C. N. Secondary malignancy after treatment of Hodgkin's disease: an evolving picture. J Clin Oncol. 1986 Jun;4(6):821–824. doi: 10.1200/JCO.1986.4.6.821. [DOI] [PubMed] [Google Scholar]
  9. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  10. Dorreen M. S., Gregory W. M., Wrigley P. F., Stansfeld A. G., Lister T. A. Second primary malignant neoplasms in patients treated for Hodgkin's disease at St Bartholomew's Hospital. Hematol Oncol. 1986 Apr-Jun;4(2):149–161. doi: 10.1002/hon.2900040207. [DOI] [PubMed] [Google Scholar]
  11. Fisher R. I., DeVita V. T., Hubbard S. P., Simon R., Young R. C. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med. 1979 May;90(5):761–763. doi: 10.7326/0003-4819-90-5-761. [DOI] [PubMed] [Google Scholar]
  12. Gribben J. G., Linch D. C., Singer C. R., McMillan A. K., Jarrett M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989 Jan;73(1):340–344. [PubMed] [Google Scholar]
  13. Hagberg H., Killander A., Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983 Jun 15;51(12):2220–2225. doi: 10.1002/1097-0142(19830615)51:12<2220::aid-cncr2820511212>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  14. Hancock B. W. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Radiother Oncol. 1986 Nov;7(3):215–221. doi: 10.1016/s0167-8140(86)80032-9. [DOI] [PubMed] [Google Scholar]
  15. Horning S. J., Hoppe R. T., Kaplan H. S., Rosenberg S. A. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med. 1981 Jun 4;304(23):1377–1382. doi: 10.1056/NEJM198106043042301. [DOI] [PubMed] [Google Scholar]
  16. Jagannath S., Armitage J. O., Dicke K. A., Tucker S. L., Velasquez W. S., Smith K., Vaughan W. P., Kessinger A., Horwitz L. J., Hagemeister F. B. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb;7(2):179–185. doi: 10.1200/JCO.1989.7.2.179. [DOI] [PubMed] [Google Scholar]
  17. Jones R. J., Piantadosi S., Mann R. B., Ambinder R. F., Seifter E. J., Vriesendorp H. M., Abeloff M. D., Burns W. H., May W. S., Rowley S. D. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1990 Mar;8(3):527–537. doi: 10.1200/JCO.1990.8.3.527. [DOI] [PubMed] [Google Scholar]
  18. Kaldor J. M., Day N. E., Clarke E. A., Van Leeuwen F. E., Henry-Amar M., Fiorentino M. V., Bell J., Pedersen D., Band P., Assouline D. Leukemia following Hodgkin's disease. N Engl J Med. 1990 Jan 4;322(1):7–13. doi: 10.1056/NEJM199001043220102. [DOI] [PubMed] [Google Scholar]
  19. Klimo P., Connors J. M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. Semin Hematol. 1988 Apr;25(2 Suppl 2):34–40. [PubMed] [Google Scholar]
  20. Klimo P., Connors J. M. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985 Sep;3(9):1174–1182. doi: 10.1200/JCO.1985.3.9.1174. [DOI] [PubMed] [Google Scholar]
  21. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630. [DOI] [PubMed] [Google Scholar]
  22. Longo D. L., Young R. C., Wesley M., Hubbard S. M., Duffey P. L., Jaffe E. S., DeVita V. T., Jr Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986 Sep;4(9):1295–1306. doi: 10.1200/JCO.1986.4.9.1295. [DOI] [PubMed] [Google Scholar]
  23. McKendrick J. J., Mead G. M., Sweetenham J., Jones D. H., Williams C. J., Ryall R., Whitehouse J. M. ChlVPP chemotherapy in advanced Hodgkin's disease. Eur J Cancer Clin Oncol. 1989 Mar;25(3):557–561. doi: 10.1016/0277-5379(89)90270-8. [DOI] [PubMed] [Google Scholar]
  24. Nicholson W. M., Beard M. E., Crowther D., Stansfeld A. G., Vartan C. P., Malpas J. S., Fairley G. H., Scott R. B. Combination chemotherapy in generalized Hodgkin's disease. Br Med J. 1970 Jul 4;3(5713):7–10. doi: 10.1136/bmj.3.5713.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ranson M. R., Radford J. A., Swindell R., Deakin D. P., Wilkinson P. M., Harris M., Johnson R. J., Crowther D. An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. Ann Oncol. 1991 Jun;2(6):423–429. doi: 10.1093/oxfordjournals.annonc.a057978. [DOI] [PubMed] [Google Scholar]
  26. Richards M. A., Waxman J. H., Man T., Ganesan T. S., Barnett M. J., Wrigley P. F., Lister T. A. EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol. 1986;18(1):51–53. doi: 10.1007/BF00253064. [DOI] [PubMed] [Google Scholar]
  27. Santoro A., Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101–105. doi: 10.1007/BF00254081. [DOI] [PubMed] [Google Scholar]
  28. Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139–143. doi: 10.7326/0003-4819-96-2-139. [DOI] [PubMed] [Google Scholar]
  29. Selby P., Patel P., Milan S., Meldrum M., Mansi J., Mbidde E., Brada M., Perren T., Forgeson G., Gore M. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer. 1990 Aug;62(2):279–285. doi: 10.1038/bjc.1990.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sherins R. J., DeVita V. T., Jr Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med. 1973 Aug;79(2):216–220. doi: 10.7326/0003-4819-79-2-216. [DOI] [PubMed] [Google Scholar]
  31. Sutcliffe S. B., Wrigley P. F., Peto J., Lister T. A., Stansfeld A. G., Whitehouse J. M., Crowther D., Malpas J. S. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J. 1978 Mar 18;1(6114):679–683. doi: 10.1136/bmj.1.6114.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sutcliffe S. B., Wrigley P. F., Stansfeld A. G., Malpas J. S. Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP). Cancer Chemother Pharmacol. 1979;2(3):209–213. doi: 10.1007/BF00258297. [DOI] [PubMed] [Google Scholar]
  33. Swan F., Jr, Velasquez W. S., Tucker S., Redman J. R., Rodriguez M. A., McLaughlin P., Hagemeister F. B., Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct;7(10):1518–1527. doi: 10.1200/JCO.1989.7.10.1518. [DOI] [PubMed] [Google Scholar]
  34. Tester W. J., Kinsella T. J., Waller B., Makuch R. W., Kelley P. A., Glatstein E., DeVita V. T. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984 Jul;2(7):762–769. doi: 10.1200/JCO.1984.2.7.762. [DOI] [PubMed] [Google Scholar]
  35. Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]
  36. Waxman J. H., Terry Y. A., Wrigley P. F., Malpas J. S., Rees L. H., Besser G. M., Lister T. A. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) 1982 Dec 4;285(6355):1612–1613. doi: 10.1136/bmj.285.6355.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES